Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 DBMR MARKET POSITION GRID
2.8 SECONDARY SOURCES
2.9 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
4.3 PIPELINE ANALYSIS
4.4 INDUSTRY INSIGHTS
4.4.1 MICRO AND MACRO ECONOMIC FACTORS
4.4.2 PENETRATION AND GROWTH PROSPECT MAPPING
4.4.3 KEY PRICING STRATEGIES
4.4.4 STRATEGIC INSIGHTS & RECOMMENDATIONS:
4.5 EPIDEMIOLOGY
4.5.1 DRUG ADHERENCE AND THERAPY SWITCH MODEL
4.5.2 PATIENT TREATMENT SUCCESS RATES
4.6 MARKETED DRUG ANALYSIS
4.6.1 DRUGS
4.6.2 BRANDED DRUGS
4.6.3 GENERIC DRUGS
4.6.4 THERAPEUTIC INDICATION
4.6.5 PHARMACOLOGICAL CLASS OF THE DRUG
4.6.6 DRUG PRIMARY INDICATION
4.6.7 MARKET STATUS
4.6.8 MEDICATION TYPE
4.6.9 DRUG DOSAGE FORM
4.6.10 DOSAGE AVAILABILITY
4.6.11 PACKAGING TYPE
4.6.12 DRUG ROUTE OF ADMINISTRATION
4.6.13 DOSING FREQUENCY
4.6.14 DRUG INSIGHT
4.6.15 OVERVIEW OF DRUG DEVELOPMENT ACTIVITIES
4.6.16 REGULATORY MILESTONE, SAFETY DATA
4.6.17 EFFICACY DATA, MARKET EXCLUSIVITY DATA
4.6.18 CROSS COMPETITION
4.6.19 THERAPEUTIC PORTFOLIO
4.6.20 CURRENT DEVELOPMENT SCENARIO
4.7 IMPORT-EXPORT ANALYSIS
4.8 SUPPLY CHAIN ECOSYSTEM
4.8.1 PROMINENT COMPANIES
4.8.2 SMALL & MEDIUM SIZE COMPANIES
4.8.3 END USERS
5 HEALTHCARE TARIFFS IMPACT ANALYSIS
5.1 OVERVIEW
5.2 TARIFF STRUCTURES
5.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS
5.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS
5.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS
5.3.3 KEY TRADE AGREEMENTS AFFECTING PHARMACEUTICAL TARIFFS
5.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS
5.4.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES
5.4.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE
5.4.3 TARIFFS AND THEIR ROLE IN MEDICAL TOURISM
5.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS
5.5.1 WTO REGULATIONS ON HEALTHCARE TARIFFS
5.5.2 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN
5.5.3 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS
5.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY
5.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR
6 REGULATORY FRAMEWORK
6.1 REGULATORY APPROVAL PROCESS
6.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
6.3 REGULATORY APPROVAL PATHWAYS
6.4 LICENSING AND REGISTRATION
6.5 POST-MARKETING SURVEILLANCE
6.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING AWARENESS AND GENETIC COUNSELING
7.1.2 ADVANCEMENTS IN CHEMOPREVENTIVE THERAPIES
7.1.3 EARLY DIAGNOSIS OF RARE DISEASE
7.1.4 RISING HEALTHCARE SPENDING AND INVESTMENT IN RARE DISEASES
7.2 RESTRAINTS
7.2.1 LIMITED PATIENT POPULATION
7.2.2 HIGH COST OF TARGETED AND PREVENTIVE THERAPIES
7.3 OPPORTUNITIES
7.3.1 PIPELINE INNOVATION FOR NON-SURGICAL OPTIONS
7.3.2 EMERGING ROLE OF LIQUID BIOPSY AND SURVEILLANCE BIOMARKERS
7.3.3 IMPROVED GENETIC TESTING AND COUNSELING
7.4 CHALLENGES
7.4.1 DIFFICULTY IN RECRUITING FOR CLINICAL TRIALS
7.4.2 INTEGRATION OF CHALLENGES INTO ESTABLISHED SURGICAL PATHWAYS
8 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 PHARMACOLOGICAL THERAPY
8.3 SURGICAL TREATMENT
8.4 GENETIC COUNSELING & MONITORING
9 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY STAGE OF DISEASE
9.1 OVERVIEW
9.2 ADVANCED COLONIC POLYPOSIS
9.3 POLYP DEVELOPMENT STAGE
9.4 POST-SURGICAL MANAGEMENT
9.5 EARLY STAGE
9.6 EXTRA-COLONIC MANIFESTATIONS
10 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 ADULT
10.3 MIDDLE-AGED
10.4 PEDIATRIC
10.5 GERIATRIC
11 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 SPECIALTY CLINICS
11.4 AMBULATORY SURGICAL CENTERS (ASCS)
11.5 ACADEMIC & RESEARCH INSTITUTES
11.6 GENETIC COUNSELING CENTERS
12 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 HOSPITAL PHARMACIES
12.3 SPECIALTY PHARMACIES
12.4 RETAIL PHARMACIES
12.5 ONLINE PHARMACIES
13 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: U.S.
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 MERCK & CO., INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.2 F. HOFFMANN-LA ROCHE LTD
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 SOLUTION PORTFOLIO
15.2.4 RECENT DEVELOPMENT
15.3 MEDTRONIC
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 PFIZER INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENT
15.5 MYRIAD GENETICS, INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 AMBRY GENETICS
15.6.1 COMPANY SNAPSHOT
15.6.2 PIPELINE PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 BOSTON SCIENTIFIC CORPORATION
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENTS
15.8 COLOR HEALTH, INC.
15.8.1 COMPANY SNAPSHOT
15.8.2 PIPELINE PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 EMTORA BIOSCIENCES
15.9.1 COMPANY SNAPSHOT
15.9.2 PIPELINE PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 ETHICON (JOHNSON AND JOHNSON)
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 INVITAE CORPORATION
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 OLYMPUS CORPORATION
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PIPELINE PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 PANBELA THERAPEUTICS, INC.
15.13.1 COMPANY SNAPSHOT
15.13.2 PIPELINE PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 RECURSION
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PIPELINE PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENT
15.15 SLA PHARMA (UK) LIMITED
15.15.1 COMPANY SNAPSHOT
15.15.2 PIPELINE PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 TAKEDA PHARMACEUTICAL COMPANY LIMITED
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PIPELINE PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 PIPELINE PRODUCTS
TABLE 2 PENETRATION AND GROWTH PROSPECT MAPPING ANALYSIS
TABLE 3 AVAILABLE THERAPY AND ADHERENCE.
TABLE 4 PATIENT TREATMENT SUCCESS RATES
TABLE 5 AVAILABLE BRANDED DRUGS
TABLE 6 AVAILABLE DRUG CLASSES
TABLE 7 MARKET STATUS
TABLE 8 DRUG DOSAGE FORM
TABLE 9 DOSING FREQUENCY
TABLE 10 CROSS COMPETITION
TABLE 11 IMPORT ANALYSIS
TABLE 12 EXPORT ANALYSIS
TABLE 13 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 14 U.S. PHARMACOLOGICAL THERAPY IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 15 U.S. NSAIDS IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 16 U.S. TARGETED THERAPY IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 17 U.S. CHEMOPREVENTIVE AGENTS IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 18 U.S. EXPERIMENTAL/INVESTIGATIONAL DRUGS IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 19 U.S. PHARMACOLOGICAL THERAPY IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 20 U.S. PHARMACOLOGICAL THERAPY IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 21 U.S. ORAL IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 22 U.S. SURGICAL TREATMENT IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 23 U.S. COLECTOMY IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 24 U.S. ENDOSCOPIC POLYPECTOMY IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 25 U.S. GENETIC COUNSELING & MONITORING IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 26 U.S. SURVEILLANCE COLONOSCOPY IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 27 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
TABLE 28 U.S. EXTRA-COLONIC MANIFESTATIONS IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 29 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 30 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 31 U.S. HOSPITALS IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 32 U.S. SPECIALTY CLINICS IN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 33 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
List of Figure
FIGURE 1 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: SEGMENTATION
FIGURE 2 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: COUNTRY-WISE MARKET ANALYSIS
FIGURE 5 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 8 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EXECUTIVE SUMMARY
FIGURE 10 THREE SEGMENTS COMPRISE THE U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, BY TREATMENT TYPE (2024)
FIGURE 11 STRATEGIC DECISIONS
FIGURE 12 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: SEGMENTATION
FIGURE 13 RISING AWARENESS AND GENETIC COUNSELING IS DRIVING THE GROWTH OF THE U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET FROM 2025 TO 2032
FIGURE 14 PHARMACOLOGICAL THERAPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET IN 2025 AND 2032
FIGURE 15 PESTLE ANALYSIS
FIGURE 16 PORTERS FIVE FORCES MODEL
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET
FIGURE 18 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY TREATMENT TYPE, 2024
FIGURE 19 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY TREATMENT TYPE, 2018-2032 (USD MILLION)
FIGURE 20 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)
FIGURE 21 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 22 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY STAGE OF DISEASE, 2024
FIGURE 23 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY STAGE OF DISEASE, 2018-2032 (USD MILLION)
FIGURE 24 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY STAGE OF DISEASE, CAGR (2025-2032)
FIGURE 25 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY STAGE OF DISEASE, LIFELINE CURVE
FIGURE 26 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY AGE GROUP, 2024
FIGURE 27 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY AGE GROUP, 2018-2032 (USD MILLION)
FIGURE 28 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY AGE GROUP, CAGR (2025-2032)
FIGURE 29 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 30 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY END USER, 2024
FIGURE 31 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY END USER, 2018-2032 (USD MILLION)
FIGURE 32 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 33 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 35 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
FIGURE 36 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 37 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 U.S. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: COMPANY SHARE 2024 (%)
